02509 荃信生物－Ｂ
QYUNS-B
QYUNS-B
| Listing Date | 2024/03/20 |
| Listing Price | 19.800 |
Quote
Subscription Result
- Subscription Rate163.15x
- Guarantee One Lot Size100 lot
- One Lot Success Rate5%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Qyuns Therapeutics Co is a clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases.
--
The Group have two Core Products, QX002N and QX005N, both of which are self-developed. QX002N is an IL-17A inhibitor and it have initiated a Phase III clinical trial for ankylosing spondylitis (AS) in China. QX005N is a monoclonal antibody (mAb) blocking IL-4R and it have initiated Phase II clinical trials for atopic dermatitis (AD), prurigo nodularis (PN) and chronic rhinosinusitis with nasal polyps (CRSwNP) in China.
--
As of 2 March 2024, it had seven other pipeline drug candidates in addition to its Core Products, four of which were in the clinical stage. Its pipeline covers four major areas in the autoimmune and allergic disease field, namely, skin, rheumatic, respiratory and digestive diseases.
--
As of 2 March 2024, it held 37 patents in China, including 31 invention patents and 6 utility models, as well as 9 patents overseas.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 12.05M H shares |
| No. of International Offer Shares | 9.91M H shares |
| No. of HK Offer Shares | 2.14M H shares |
| Offer Price | $19.80 - $20.2 |
| Stock Code | 2509 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, Essence International Securities (Hong Kong) Limited, Guotai Junan Securities (Hong Kong) Limited, Huatai Financial Holdings (Hong Kong) Limited, China Industrial Securities International Capital Limited, Livermore Holdings Limited, Tiger Brokers (HK) Global Limited, Fosun International Securities Limited, Citrus Securities Limited, SPDB International Capital Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Hong Tai Securities Limited |
TIME TABLE
| Application Period | Mar 12 (Tue) - noon, Mar 15 (Fri) |
| Price Determination Date | Mar 18 (Mon) |
| Result Announcement Date | On or before Mar 19 (Tue) |
| Result Announcement Date | On or before Mar 19 (Tue) |
| Result Announcement Date | On or before Mar 20 (Wed) |
| Dealings in Shares commence on | Mar 20, 2024. (Wed) |
Reallocation of Shares Offered
| Times of HK Offer Shares Subscription | 15X - 50X | 50X - 100X | Over 100X |
| % of total shares reallocated to HK Offer | 30% | 40% | 50% |
Sales Statistics (HKD)
| Offer Price | $19.80 - $20.2 |
| Capitalization | 4.40B - 4.49B |
| NAV / share ($) | $2.86 - $2.88 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 20.00, the net proceeds raised would be HKD 163.50M, of which |
| 30.1% : Ｄevelopment and registration of Core Product, QX002N |
| 54.6% : Development and registration of other Core Product, QX005N |
| 8.7% : Development and registration of QX004N |
| 1.9% : Clinical development of QX006N |
| 4.7% : Research and development of certain of other assets, including QX007N, QX010N and QX013N, and drug discovery |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).